Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Plus Hydroxyurea in Progressive GBM
NCT00290771Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in glioblastoma multiforme (GBM), sponsored by Novartis. Started Feb 2006; status: terminated.
02
Drugs
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00290771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290771.